Logo Promisme

The Project

2 1

Transforming the Landscape of Protein Misfolding Diseases

ProMisMe is a cutting-edge EU-funded research initiative dedicated to transform the landscape of Protein Misfolding Diseases (PMDs). Leveraging the latest breakthroughs in disease mechanism understanding and the innovative strides in biomolecular engineering and synthetic biology, ProMisMe is set to revolutionize therapeutic discovery for these elusive conditions.

5

Pioneering Therapeutic Discovery

At ProMisMe, we are committed to developing groundbreaking technologies that pave the way for discovering potent therapeutic molecules. Our focus is on the misfolding-prone membrane proteins (MisMPs), a particularly challenging class of proteins and diseases that have notoriously been difficult to target.

3

Harnessing Synthetic Biology for Innovation

ProMisMe harnesses the power of synthetic biology to create an innovative platform for the rapid production and screening of extensive libraries of cyclic oligopeptides. These emerging therapeutic molecules hold great promise in identifying inhibitors (rescuers) that can counteract the harmful misfolding of integral membrane proteins.

ProMisMe

Why It Matters

Protein misfolding lies at the heart of many devastating diseases. By targeting the root causes with precision and innovation, ProMisMe aims to transform the treatment landscape for patients suffering from these debilitating conditions and advance the frontiers of biomedical science forward.

ProMisMe is dedicated to discovering therapeutic candidates for two severe PMDs: Usher Syndrome III and Charcot-Marie-Tooth disease. Success in this project will not only provide promising therapeutic leads against these major diseases but also establish a broadly applicable framework for drug discovery targeting various conditions caused by membrane protein misfolding.
ProMisMe

Our Approach

The primary objective of ProMisMe is to develop engineered yeast (Saccharomyces cerevisiae) that serve as discovery platform for compounds capable of rescuing MisMP misfolding. These compounds are sourced from vast libraries of drug-like molecules biosynthesized within these microbes, leveraging a technology that allows for the rapid production and screening of a vast diversity of test molecules. These libraries are screened in the microbial cells that produce them, and the molecules that effectively rescue MisMP misfolding are selected through ultrahigh-throughput screening.